Clene Inc.: Promising Future with CNM-Au8 Advancements and Strategic Financial Management

Tip Ranks
2025.11.15 14:55
portai
I'm PortAI, I can summarize articles.

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Clene Inc., with a $20 price target, citing advancements in CNM-Au8 for neurological disorders and strategic financial management. Clene's stock has risen 220.30% in six months. Roth MKM also maintained a Buy rating with a $30 target. CNM-Au8's Orphan Drug Designation could expedite FDA approval by late 2026, making Clene a compelling buy opportunity.

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Clene, with a price target of $20.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Naz Rahman has given his Buy rating due to a combination of factors that highlight Clene’s promising future. The company is advancing its lead asset, CNM-Au8, a gold-based nanocrystal suspension, in treating neurological disorders such as ALS. The anticipation of near-term data readouts and a subsequent NDA filing in the first quarter of 2026 positions Clene for potential regulatory milestones, which could significantly enhance its market value.
Clene’s strategic financial management, including recent fundraising efforts, ensures sufficient capital to support operations through these critical phases. The Orphan Drug Designation for CNM-Au8 could expedite its review process, potentially leading to an FDA Advisory Committee meeting and approval by the latter half of 2026. Given the limited treatment options for ALS and the promising data from Clene’s clinical trials, Rahman believes CNM-Au8 has a high probability of approval, making Clene’s stock a compelling buy opportunity.

In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $30.00 price target.

CLNN’s price has also changed dramatically for the past six months – from $2.660 to $8.520, which is a 220.30% increase.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.